Press room

Vytrus in the media
Press releases

25/10/2023

Vytrus Biotech signs with CDTI a 575,000€ funding for R&D projects in dermocosmetics and health

The biotech company has received 575,000€ in funding from the CDTI for the development of new cutting-edge technologies in the field of dermocosmetics and health.

PDF

13/07/2023

Bronze Best Ingredient Award for Vytrus at in-cosmetics Korea 2023

Vytrus Biotech has been awarded with the Bronze Best Ingredient Award for its active PHOTOBIOME™ at in-cosmetics Korea 2023, the leading event for personal care ingredients in the region.

PDF

31/05/2023

Vytrus Biotech nominated for the European Small and Mid-Cap Awards 2023

BME Growth has submitted the biotech company's candidacy for the Rising Star category for the European Small and Mid-Cap awards, the benchmark awards for European stock markets.

PDF

28/03/2023

Vytrus Biotech increases its sales its sales by 31% in 2022

The company closed 2022 with a 30% increase in EBITDA to €1.5 million. In its first year of trading on BME Growth, the biotechnology company has appreciated 98%, the second highest increase on the Spanish stock market.

PDF

26/01/2023

Vytrus Biotech receives valuation of 26.4 million euros according to GVC Gaesco

The biotechnology company has received a valuation report from GVC Gaesco Valores, which estimates a target price of 3.71€/share December 2023e for the company, equivalent to 26.4 million euros, 10% more than yesterday's closing price.

PDF

03/01/2023

Vytrus registers its first patent in Europe, USA and Japan for hair loss

Europe, USA and Japan have granted the Spanish stock market-listed company with a patent in the field of hair loss prevention and treatment, framed within the proprietary firm’s biotechnology platform called Phyto-Peptidic Fractions. Through this platform, Vytrus has developed several active ingredients from plant stem cells for applications in skincare and haircare.

PDF

2/11/2022

Silver Best Ingredient Award for Vytrus at in-cosmetics Asia 2022

Vytrus Biotech has been awarded with the Silver Best Ingredient Award for its natural active ELAYA RENOVA™ at in-cosmetics Asia 2022, the leading event for personal care ingredients in the region.

PDF

20/10/2022

Vytrus Biotech increases its sales by 51% in the first half of 2022

The company has closed the first half of 2022 with a turnover of 2.04 million euros, a record for the firm, and gross operating profit (Ebitda) of 860 thousand, 62% more than in the same period of the previous year, as reported to the market.

PDF

30/09/2022

Vytrus awarded first position at Cosmetorium Awards 2022

The biotech company has been awarded with the first position at Cosmetorium 2022 for its innovation with a cosmetic formulation containing QUORA NONI™ biomics, a new ingredient that rejuvenates the skin microbiota to achieve a younger-looking skin.

PDF

22/09/2022

Gold Best Ingredient Award for Vytrus at in-cosmetics Latin America 2022

Vytrus Biotech has been awarded with the Gold Best Ingredient Award for its natural active ELAYA RENOVA™ at in-cosmetics Latin America 2022, the leading event for personal care ingredients in the region.

PDF

26/05/2022

First position at BBVA Sustainable Innovation Award for Vytrus

Vytrus Biotech has been recognized with the first position at BBVA Award to the Innovation in Environmental Sustainability for its environmentally friendly business model.

PDF

25/04/2022

Vytrus increases its net profit by more than 100% in 2021

The biotechnology company has closed 2021 financial year with the best results in its history by rising its net profit by 100%. Vytrus also increased its market value by 100% in its first trading month.

PDF

15/03/2022

Vytrus rises more than 25% in its stock market debut on March 15th

Vytrus Biotech has been listed in BME Growth and increases its market value by more than 25% in its first trading day.

PDF

25/01/2022

Vytrus announces its intention to be listed in BME Growth and a 65% sales increase

The biotechnology company is finalizing the procedures for its launch on the alternative stock market (BME Growth) in the coming months.

PDF

24/05/2021

Vytrus increases its sales by 40% and triples its EBITDA in 2020

Vytrus has broken its own record and sales forecasts, reaching 1.7 million euros at the end of 2020, while increasing its EBITDA by 200% in the same period.

PDF

28/02/2020

Vytrus Biotech raises €1.7M and turns into an industrial company

The Spanish company, specialised in active ingredients for the cosmetic sector, reaches €1.22M on sales and expects to increase its turnover by 23% in 2020

PDF